Teva Pharmaceutical Industries Ltd. Chief Accounting Officer Amir Weiss filed a Form 4 on November 12, 2026, reporting the exercise of stock options and the sale of ordinary shares on November 9, 2026.
Key Highlights
- Option exercise: Weiss acquired 7,755 ordinary shares on November 9, 2026, via the exercise of stock options (transaction code M) at an exercise price of $34.70 per share.
- Share sales: Weiss disposed of a total of 17,289 ordinary shares across three separate sale transactions on the same date.
- Sale prices: The three disposals were executed at $43.15 per share (662 shares), a weighted average of $43.0349 per share (7,093 shares), and a weighted average of $43.0289 per share (9,534 shares).
- Remaining holdings: Following all reported transactions, Weiss directly held 3,537 ordinary shares.
- Options extinguished: The exercised options, originally granted on March 3, 2017, were fully disposed of, leaving Weiss with 0 stock options beneficially owned.
- Issuer: The filing identifies the issuer as Teva Pharmaceutical Industries Ltd., traded on NYSE:TEVA.
Weiss Option Exercise and Share Disposals Detailed
According to the filing, Amir Weiss, identified as Chief Accounting Officer of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), reported four transactions on November 9, 2026. First, he exercised stock options to acquire 7,755 ordinary shares at a conversion price of $34.70, bringing his directly held ordinary shares to 20,826 following that transaction.
The filing then reports three sequential sales. Weiss sold 662 shares at $43.15 per share, reducing his directly held position to 20,164. He then sold 7,093 shares at a weighted average price of $43.0349, with the filing noting those shares were sold in multiple transactions at prices ranging from $43.02 to $43.05, inclusive. A third sale of 9,534 shares followed at a weighted average price of $43.0289, with prices ranging from $43.025 to $43.04, inclusive. After all three sales, the filing reports his direct beneficial ownership at 3,537 ordinary shares.
Regarding the options exercised, the filing states they were granted on March 3, 2017. Per the footnote, 1,938 shares vested on each of March 3, 2018, March 3, 2019, and March 3, 2020, and 1,941 shares vested on March 3, 2021, with an expiration date of March 3, 2027. Following the exercise, Weiss holds 0 stock options. The Form 4 was signed by Dov Bergwerk as attorney-in-fact for Amir Weiss and filed on November 12, 2026.
What Was Disclosed
The filing discloses that Teva's Chief Accounting Officer Amir Weiss exercised 7,755 stock options and sold a combined 17,289 ordinary shares on November 9, 2026, leaving him with a direct beneficial ownership of 3,537 ordinary shares and zero remaining stock options.




Please wait processing your request...